Analyst firms · Jefferies · ALGS
Jefferies ALGS price target and rating history
Aligos Therapeutics Inc. (ALGS) · Health Care
Jefferies rates Aligos Therapeutics Inc. (ALGS) Buy with a $48 price target, as of its latest action on Mar 19, 2026. It has published 3 rating actions on ALGS since January 2022, including 1 upgrade and 1 downgrade. Across 3 firms with a ALGS price target in the last 12 months, the median target is $45. Jefferies's $48 is 7% above that.
- Current rating
- Buy
- Price target
- $48
- Median target, all firms
- $45
- Actions on ALGS
- 3
Jefferies price target on ALGS
Every Jefferies rating on ALGS
- Mar 19, 2026
- Jan 6, 2023
- Jan 6, 2022
How other firms rate ALGS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Lake Street | Buy | $45 | May 28, 2026 |
| Cantor Fitzgerald | Overweight | $20 | May 21, 2026 |
| Jefferies | Buy | $48 | Mar 19, 2026 |
Questions about Jefferies and ALGS
- What is Jefferies's price target for ALGS?
- Jefferies's latest stated price target for Aligos Therapeutics Inc. (ALGS) is $48, from its action on Mar 19, 2026.
- What is Jefferies's rating on ALGS?
- Jefferies rates ALGS Buy, a bullish rating, as of Mar 19, 2026.
- When did Jefferies last change its view on ALGS?
- On Mar 19, 2026, Jefferies resumes coverage at Buy, price target $48.
- How does Jefferies's ALGS target compare with other analysts?
- Across 3 firms with a ALGS price target in the last 12 months, the median target is $45. Jefferies's $48 is 7% above that.
More ALGS rating histories
All Jefferies ratingsALGS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.